Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1

Antiviral Research

Volumn 92, Issue 3, 2011, Pages 479-483

  González Ortega, Emmanuel ^a   Ballana, Ester ^a   Badia, Roger ^a   Clotet, Bonaventura ^a   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Fitness; Fusion; gp41; HIV 1; Resistance

Indexed keywords

ENFUVIRTIDE; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS INHIBITORY PEPTIDE; ZIDOVUDINE; ALPHA 1 ANTITRYPSIN; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PEPTIDE FRAGMENT; VIR 353; VIR-353; VIRIP PEPTIDE, HUMAN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; CELL LINE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; MICROBIOLOGICAL EXAMINATION; MOLECULAR GENETICS; MUTATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; VIR;

ALPHA 1-ANTITRYPSIN; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CELL LINE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; VIRUS REPLICATION;

EID: 84858736184     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.10.010     Document Type: Article

References (24)

1. Armand-Ugon M., Gutierrez A., Clotet B., Esté J.A. HIV-1 resistance to the gp41-dependent fusion inhibitor C-34. Antiviral Res. 2003, 59:137-142.
2. Armand-Ugón M., Clotet-Codina I., Tintori C., Manetti F., Clotet B., Botta M., Esté J.A. The anti-HIV activity of ADS-J1 targets the HIV-1 gp120. Virology 2005, 343:141-149.
3. Armand-Ugón M., Moncunill G., Mena M.P., Gonzalez E., Ballana E., Clotet B., Esté J.A. Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5. J. Antimicrob. Chemother. 2010, 65:417-424.
4. Ballana E., Pauls E., Senserrich J., Clotet B., Perron-Sierra F., Tucker G.C., Esté J.A. Cell adhesion through alphaV-containing integrins is required for efficient HIV-1 infection in macrophages. Blood 2009, 113:1278-1286.
5. Ballana E., Pauls E., Perron-Sierra F., Clotet B., Tucker G., Esté J.A. Beta5 integrin is the major contributor to the αVintegrin-mediated blockade of HIV-1 replication. J. Immunol. 2011, 186:464-470.
6. Blumenthal R., Dimitrov D.S. Targeting the sticky fingers of HIV-1. Cell 2007, 129:243-245.
7. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 2010, 85:1-18.
8. Esté J.A., Telenti A. HIV entry inhibitors. Lancet 2007, 370:81-88.
9. Esté J.A., Cabrera C., Blanco J., Gutierrez A., Bridger G., Henson G., Clotet B., Schols D., De Clercq E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J. Virol. 1999, 73:5577-5585.
10. Férir G., Vermeire K., Huskens D., Balzarini J., Van Damme E.J., Kehr J.C., Dittmann E., Swanson M.D., Markovitz D.M., Schols D. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs). Antiviral Res. 2011, 90:200-204.
11. Fernandez-Piñas, F., Rosal, R., Leganies, F., Petre, A., Boltes, k., Rodea-Palomares, I., Perdigón-Melón, J.A., 2010. Application of the combination index (CI)-isobologram equation to study the toxicological interactions of pollutants in aquatic organisms. SciTopics, /Application_of_the_combination_index_CI_isobologram_equation_to_study_the_toxicological_interactions_of_pollutants_in_aquatic_organisms.html. Retrieved September 2, 2011. http://www.scitopics.com.
12. Forssmann W.G., The Y.H., Stoll M., Adermann K., Albrecht U., Barlos K., Busmann A., Canales-Mayordomo A., Gimenez-Gallego G., Hirsch J., Jimenez-Barbero J., Meyer-Olson D., Münch J., Perez-Castells J., Ständker L., Kirchhoff F., Schmidt R.E. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci. Transl. Med. 2010, 2:63.
13. Gonzalez E., Ballana E., Clotet B., Esté J. Development of resistance to VIR353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP). AIDS 2011, 25:1557-1583.
14. Greenberg M.L., Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J. Antimicrob. Chemother. 2004, 54:333-340.
15. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., Nadler J., Clotet B., Karlsson A., Wohlfeiler M., Montana J.B., McHale M., Sullivan J., Ridgway C., Felstead S., Dunne M.W., van der Ryst E., Mayer H. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008, 359:1429-1441.
16. He Y., Cheng J., Lu H., Li J., Hu J., Qi Z., Liu Z., Jiang S., Dai Q. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc. Natl. Acad. Sci. USA 2008, 105:16332-16337.
17. He Y., Xiao Y., Song H., Liang Q., Ju D., Chen X., Lu H., Jing W., Jiang S., Zhang L. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 2008, 283:11126-11134.
18. Menendez-Arias L. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 2010, 85:210-231.
19. Menendez-Arias L., Esté J.A. HIV-resistance to viral entry inhibitors. Curr. Pharm. Des. 2004, 10:1845-1860.
20. Moncunill G., Armand-Ugon M., Clotet-Codina I., Pauls E., Ballana E., Llano A., Romagnoli B., Vrijbloed J.W., Gombert F.O., Clotet B., De Marco S., Esté J.A. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. Mol. Pharmacol. 2008, 73:1264-1273.
21. Moncunill G., Armand-Ugon M., Pauls E., Clotet B., Esté J.A. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro. AIDS 2008, 22:23-31.
22. Münch J., Ständker L., Adermann K., Schulz A., Schindler M., Chinnadurai R., Pohlmann S., Chaipan C., Biet T., Peters T., Meyer B., Wilhelm D., Lu H., Jing W., Jiang S., Forssmann W.G., Kirchhoff F. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007, 129:263-275.
23. Pannecouque C., Daelemans D., De Clercq E. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat. Protocols 2008, 3:427-434.
24. Tilton J.C., Doms R.W. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010, 85:91-100.